Incorporating BCNU wafers into malignant glioma treatment: European case studies

Clinical Drug Investigation

Volumn 30, Issue 3, 2010, Pages 195-204

  Balossier, Anne ^a   Dörner, Lutz ^b   Emery, Evelyne ^a   Heese, Oliver ^c   Mehdorn, H Maximilian ^b   Menei, Philippe ^d   Singh, Jagmohan ^e  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CORTICOSTEROID; IMATINIB; METHYLPREDNISOLONE; TEMOZOLOMIDE;

ADULT; ARTICLE; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG IMPLANTATION; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTHERMIA; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG IMPLANTS; EUROPE; FEMALE; GLIOMA; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME;

EID: 77249166580     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11532900-000000000-00000     Document Type: Article

References (51)

1. Boyle P, Levin B, editors. World cancer report 2008. Lyon: International Agency for Research on Cancer, 2008
2. Rachet B, Mitry E, Quinn MJ, et al. Survival from brain tumours in England and Wales up to 2001. Br J Cancer 2008 Sep 23; 99 Suppl. 1: S98-101
3. UK brain and central nervous system cancer incidence statistics [online]. Available from URL: http://info.cancer researchuk.org/cancerstats/types/brain/ incidence/ [Accessed 2009 Jan 4]
4. Bauchet L, Rigau V, Mathieu-Daude H, et al. French brain tumor data bank: methodology and first results on 10,000 cases. J Neurooncol 2007 Sep; 84 (2): 189-199
5. Ekman M, Westphal M. Cost of brain tumour in Europe. Eur J Neurol 2005 Jun; 12 Suppl. 1: 45-49
6. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005 Jan; 109 (1): 93-108
7. Stupp R, Roila F. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008 May; 19 Suppl. 2: ii83-5
8. Sant M, Aareleid T, Berrino F, et al. EUROCARE-3: survival of cancer patients diagnosed 1990-9 - results and commentary. Ann Oncol 2003; 14 Suppl. 5: v61-118
9. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTCNCIC trial. Lancet Oncol 2009May; 10 (5): 459-466
10. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005 Jun; 64 (6): 479-489
11. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980 Sep; 30 (9): 907-911
12. Kochi M, Ushio Y. High-dose chemotherapy with autologous hematopoietic stem-cell rescue for patients with malignant brain tumors. Crit Rev Neurosurg 1999 Sep 24; 9 (5): 295-302
13. Petersdorf SH, Livingston RB. High dose chemotherapy for the treatment of malignant brain tumors. J Neurooncol 1994; 20 (2): 155-163
14. Zucchetti M, Boiardi A, Silvani A, et al. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother Pharmacol 1999; 44 (2): 173-176
15. Gumerlock MK, Belshe BD, Madsen R, et al. Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review. J Neurooncol 1992 Jan; 12 (1): 33-46
16. Rapoport SI. Osmotic opening of the blood-brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 2000 Apr; 20 (2): 217-230
17. Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983 Feb; 67 (2): 121-132
18. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.NEngl J Med 1980 Dec 4; 303 (23): 1323-1329
19. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003 Apr; 5 (2): 79-88
20. Lin SH, Kleinberg LR. Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 2008 Mar; 8 (3): 343-359
21. Grossman SA, Reinhard C, Colvin OM, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992 Apr; 76 (4): 640-647
22. Dang W, Daviau T, Brem H. Morphological characterization of polyanhydride biodegradable implant Gliadel during in vitro and in vivo erosion using scanning electron microscopy. Pharm Res 1996 May; 13 (5): 683-691
23. Fung LK, Ewend MG, Sills A, et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998 Feb 15; 58 (4): 672-684
24. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002; 41 (6): 403-419
25. Sampath P, Brem H. Implantable slow-release chemotherapeutic polymers for the treatment of malignant brain tumors. Cancer Control 1998 Mar; 5 (2): 130-137
26. Gururangan S, Cokgor L, Rich JN, et al. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro Oncol 2001 Oct; 3 (4): 246-250
27. Welcome healthcare professionals [online]. Available from URL: http://www.gliadel.com/hcp/default.aspx [Accessed 2009 Nov 4]
28. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995 Apr 22; 345 (8956): 1008-1012
29. Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006 Mar; 148 (3): 269-75; discussion 75
30. Do V, Gebski V, Barton MB. The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol 2000 Nov; 57 (2): 131-136
31. Gliadel 7.7 mg implant summary of product characteristics [online]. Available from URL: http://emc.medicines.org. uk/emc/assets/c/html/DisplayDoc. asp?DocumentID=13913 [Accessed 2009 Jan 6]
32. Temodal: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/human docs/Humans/EPAR/temodal/temodal.htm [Accessed 2009 Nov 4]
33. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 Mar 10; 352 (10): 987-996
34. Ashby LS, Ryken TC. Management of malignant glioma: steady progress with multimodal approaches. Neurosurg Focus 2006; 20 (4): E3
35. La Rocca RV, Mehdorn HM. Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr Med Res Opin 2009; 25 (1): 149-160
36. Spiegel BM, Esrailian E, Laine L, et al. Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: a meta-analysis. CNS Drugs 2007; 21 (9): 775-787
37. McGirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 2009 Mar; 110 (3): 583-588
38. Pan E, Mitchell SB, Tsai JS. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol 2008 Jul; 88 (3): 353-357
39. Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma [online]. Available from URL: http://www.nice.org.uk/ nicemedia/pdf/TA121 quickrefguide.pdf [Accessed 2009 Jan 6]
40. Engelhard HH. Tumor bed cyst formation after BCNU wafer implantation: report of two cases. Surg Neurol 2000 Mar; 53 (3): 220-224
41. McGirt MJ, Villavicencio AT, Bulsara KR, et al. Management of tumor bed cysts after chemotherapeutic wafer implantation: report of four cases. J Neurosurg 2002 May; 96 (5): 941-945
42. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000 Nov 9; 343 (19): 1350-1354
43. Gerson SL. Clinical relevance of MGMT in the treatment of cancer. J Clin Oncol 2002 May 1; 20 (9): 2388-2399
44. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990 Oct 1; 50 (19): 6119-6129
45. Mitchell RB, Dolan ME. Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 1993; 32 (1): 59-63
46. Plowman J, Waud WR, Koutsoukos AD, et al. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 1994 Jul 15; 54 (14): 3793-3799
47. Rhines LD, Sampath P, Dolan ME, et al. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma. Cancer Res 2000 Nov 15; 60 (22): 6307-6310
48. Hegi ME, Liu L, Herman JG, et al. Correlation of O6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008 Sep 1; 26 (25): 4189-4199
49. Hoelzinger DB, Demuth T, Berens ME. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 2007 Nov 7; 99 (21): 1583-1593
50. Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. CurrMed Res Opin 2008 Oct 20; 24 (11): 3239-3257
51. Evans D. Hierarchy of evidence: a framework for ranking evidence evaluating healthcare interventions. J Clin Nurs 2003 Jan; 12 (1): 77-84